Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03441438
Other study ID # 20382
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2018
Est. completion date September 1, 2018

Study information

Verified date May 2018
Source University of Virginia
Contact BJ Ferrebee-Ghamandi, MHA
Phone 434-243-1558
Email Bjf8j@hscmail.mcc.virginia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine what type of reactions in the body may be responsible for the respiratory symptoms that occur when patients with Aspirin Exacerbated Respiratory Disease (AERD) drink alcoholic beverages. These reactions are most often seen with red wine.


Description:

This is a prospective trial of approximately 60 subjects with AERD to explore the mechanisms behind the physiologic reactions that occur when drinking alcoholic beverages. At various time points patients will be asked to ingest a variety of substances found in red wine after which blood and urine markers of the reaction will be measured.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 1, 2018
Est. primary completion date September 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Healthy Controls - must be 21 years or older

- Aspirin Tolerant Asthma and AERD arms must note a sensitivity to alcoholic beverages

Exclusion Criteria:

- Enzymopathies

- Mastocytosis

- Alcoholism

- Prior severe respiratory reaction to alcohol consumption

- Current pregnancy

- Monoamine Oxidase Inhibitor (MAOI) use

- Age under 21

- Use of leukotriene modifier 1 week before study intervention

- Having undergone and maintained aspirin desensitization

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Water
Serum and urine markers will be obtained after drinking 5 oz of water
Red wine
Serum and urine markers will be obtained after drinking 5 oz of water
Polyphenolic Compounds
Serum and urine markers will be obtained after consuming 100 mg of provinols powder

Locations

Country Name City State
United States University of Virginia Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cardet JC, White AA, Barrett NA, Feldweg AM, Wickner PG, Savage J, Bhattacharyya N, Laidlaw TM. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):208-13.. doi: 10.1016/j.jaip.2013.12.003. — View Citation

Payne SC. Re: Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):644. doi: 10.1016/j.jaip.2014.05.003. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 24 Hour Urinary Leukotriene-E4 (LTE4) Urine LTE4 ng/mg Cr 24 hour
Secondary 24 Hour Urinary Prostaglandin-D2 (PGD2) metabolite Urine PGD2 metabolite ng/mg Cr 24 hour collection
Secondary Whole blood Activated Basophil Level Proportion of activated basophils in whole blood after ingestion 2 hours after ingestion
Secondary Whole Blood Activated Eosinophil Level Proportion of activated eosinophils in whole blood after ingestion 2 hours after ingestion
Secondary Whole Blood tryptase Level of tryptase concentration in whole blood 2 hours after ingestion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03973749 - Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD N/A
Withdrawn NCT01615536 - The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus N/A
Recruiting NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Phase 2
Completed NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2